Coherus Oncology, Inc. Common Stock (CHRS) Stock Price

CHRSStock

$0.99−42.11%52W

Market Cap$152.96M

P/E0.91x

PEG Ratio—

Div yield—

Beta1.00

CHRS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-54.91%

Price vs S&P 500 (4W)-26.41%

VGM Score52.45

P/E Ratio (Annual)0.91x

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)11.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-41.53%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)-42.21%

Gross Margin (TTM)68.94%

Net Profit Margin (TTM)-259.41%

EPS (TTM)$-1.03

10-Day Avg Trading Volume1.66M

EPS Excl Extra (TTM)$-1.03

Revenue Growth (5Y)-38.41%

EPS (Annual)$1.43

ROI (Annual)149.90%

Gross Margin (Annual)67.24%

Net Profit Margin (5Y Avg)18.09%

Cash / Share (Quarterly)$0.68

P/E Basic Excl Extra (TTM)1.05x

Revenue Growth QoQ (YoY)39.53%

EPS Growth (5Y)-1.96%

P/E Normalized (Annual)0.91x

ROA (Last FY)65.04%

Revenue Growth TTM (YoY)-64.32%

EBITD / Share (TTM)$-1.18

ROE (5Y Avg)-127.02%

Operating Margin (TTM)-311.56%

Cash Flow / Share (Annual)$-1.14

P/B Ratio2.51x

P/B Ratio (Quarterly)3.55x

Net Income / Employee (Annual)$1,143,000

EV / Revenue (TTM)2.39x

Net Interest Coverage (TTM)-33.01x

ROA (TTM)-42.90%

EV / EBITDA (TTM)2.12x

EPS Incl Extra (Annual)$1.43

Current Ratio (Annual)1.47x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume1.16M

52-Week Price Return-42.11%

P/E Incl Extra (TTM)1.05x

Revenue / Employee (TTM)$346,500

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)3.63x

Asset Turnover (Annual)0.16x

52-Week High$2.62

Operating Margin (5Y Avg)-158.70%

EPS Excl Extra (Annual)$1.43

Tangible BV CAGR (5Y)-3.76%

26-Week Price Return-45.00%

Quick Ratio (Annual)1.36x

13-Week Price Return-29.29%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)1.77x

Enterprise Value$121.80M

Revenue / Share Growth (5Y)-42.44%

Asset Turnover (TTM)0.17x

Book Value / Share Growth (5Y)2.39%

Revenue / Employee (Annual)$286,900

Inventory Turnover (Annual)0.38x

Pretax Margin (Annual)-434.23%

Cash / Share (Annual)$1.42

3-Month Return Std Dev74.74%

Gross Margin (5Y Avg)52.25%

Net Income / Employee (TTM)$-898,900

EBITDA CAGR (5Y)-13.04%

ROE (Last FY)275.39%

Net Interest Coverage (Annual)-18.03x

EPS Basic Excl Extra (Annual)$1.43

P/FCF (TTM)1.73x

Receivables Turnover (TTM)5.36x

Total Debt / Equity (Quarterly)0.85x

EPS Incl Extra (TTM)$-1.03

Receivables Turnover (Annual)0.65x

ROI (TTM)-107.16%

P/S Ratio (TTM)3.00x

Pretax Margin (5Y Avg)-166.75%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$0.12

Price vs S&P 500 (52W)-57.64%

P/E Ratio (TTM)1.05x

EPS Growth TTM (YoY)735.87%

Year-to-Date Return-30.28%

5-Day Price Return-3.88%

EPS Normalized (Annual)$1.43

ROA (5Y Avg)-13.87%

Net Profit Margin (Annual)398.43%

Month-to-Date Return-18.18%

Cash Flow / Share (TTM)$-2.49

EBITD / Share (Annual)$-1.51

Operating Margin (Annual)-429.51%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-6.87%

P/E Excl Extra (TTM)1.05x

LT Debt / Equity (Quarterly)0.85x

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)13.63x

P/B Ratio (Annual)2.81x

Inventory Turnover (TTM)3.11x

Pretax Margin (TTM)-316.37%

Book Value / Share (Annual)$0.50

Price vs S&P 500 (13W)-31.97%

Net Margin Growth (5Y)70.34%

Beta1.00x

P/FCF (Annual)1.04x

Revenue / Share (TTM)$0.33

ROE (TTM)-183.36%

52-Week Low$0.97

vGradeB

gGradeC

mGradeC

vgmGradeC

CHRS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.12	-$0.19	-65.22%(-$0.08)
Q1 2026	May 11, 2026	-$0.27	-$0.25	+5.66%(+$0.02)
Q4 2025	Mar 9, 2026	-$0.34	-$0.34	-1.49%(-$0.01)
Q3 2025	Nov 6, 2025	-$0.29	-$0.33	-13.79%(-$0.04)
Q2 2025	Aug 7, 2025	-$0.27	-$0.34	-25.19%(-$0.07)

CHRS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.23

4.17

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CHRSCoherus Oncology, Inc. Common Stock	B	C	C	3.0x	-64.3%	68.9%	-2.0%	$0.99
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Coherus Oncology, Inc. Common Stock

Coherus Oncology is a commercial-stage biotechnology company with LOQTORZI, an approved PD-1 inhibitor, and a pipeline of two mid-stage clinical candidates. The company is expanding LOQTORZI's use in nasopharyngeal cancer and exploring combination therapies with its pipeline candidates and industry partners. Key assets include LOQTORZI, CHS-114, and Casdozokitug, targeting liver, lung, head and neck, and other cancers.